Related Experiment Video
Updated: Jul 20, 2026
Treating SCA1 Mice with Water-Soluble Compounds to Non-Specifically Boost Mitochondrial Function
Published on: January 22, 2017
Infant mice with glutaric acidaemia type I have increased vulnerability to 3-nitropropionic acid toxicity
K B Bjugstad1, L S Crnic, S I Goodman
1Department Psychiatry, University of Colorado Health Sciences Center, Denver, Colorado, USA. Kimberly.Bjugstad@UCHSC.edu
Insights
Glutaric acidaemia type I (GA I) involves a metabolic deficiency. Researchers found GCDH-deficient mice are more vulnerable to 3NP, suggesting a model for striatal degeneration in GA I.
Area of Science:
- Biochemistry
- Neuroscience
- Metabolic Disorders
Background:
- Glutaric acidaemia type I (GA I) is an inherited metabolic disorder.
- It results from glutaryl-CoA dehydrogenase (GCDH) deficiency.
- GA I clinically presents with striatal degeneration in early childhood.
Purpose of the Study:
- To investigate 3-Nitropropionic acid (3NP) as a potential trigger for striatal degeneration in GCDH-deficient mice.
- To explore the developmental susceptibility to 3NP in a murine model of GA I.
Main Methods:
- Utilized a murine knockout model for GA I (GCDH-deficient mice).
- Administered 3-Nitropropionic acid (3NP), a succinic dehydrogenase inhibitor, to mouse pups.
- Compared susceptibility to 3NP between GCDH-deficient and wild-type mice across different age groups.
Main Results:
- GCDH-deficient mouse pups exhibited increased susceptibility to 3NP compared to wild-type littermates.
- All mouse pups showed higher sensitivity to 3NP during infancy compared to adolescence and adulthood.
- These findings suggest an early-life developmental window for striatal damage.
Conclusions:
- Early-life increased sensitivity to 3NP in GCDH-deficient mice may replicate the developmental window for striatal damage in human GA I.
- This study provides a potential model for understanding the pathogenesis of striatal degeneration in GA I.
Abstract:
Glutaric acidaemia type I (GA I) is an inborn error of metabolism caused by a deficiency of glutaryl-CoA dehydrogenase (GCDH) and is characterized clinically by striatal degeneration that almost always occurs in early childhood. A murine knockout model of GA I has the organic aciduria seen in the human disorder, but this model does not develop striatal degeneration spontaneously. 3-Nitropropionic acid (3NP), a succinic dehydrogenase inhibitor with specificity for the striatum, was investigated as a potential initiator of striatal degeneration in GCDH-deficient mice. This study shows that GCDH-deficient mouse pups are more susceptible to 3NP than their wild-type littermates, and that all mouse pups are more sensitive to 3NP as infants than as adolescents and adults. Increased sensitivity to 3NP early in life may model the developmental window for the striatal damage observed in human GA I.
